Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04PSL
|
||||
| Former ID |
DIB011118
|
||||
| Drug Name |
FINROZOLE
|
||||
| Synonyms |
MPV-2213ad; Finrozole < Prop INN >; Rac-(R*,S*)-4-[3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Prostate disease [ICD10:N42.9] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H15FN4O
|
||||
| Canonical SMILES |
OC(Cc1ccc(F)cc1)C(c2ccc(cc2)C#N)n3cncn3
|
||||
| InChI |
1S/C18H15FN4O/c19-16-7-3-13(4-8-16)9-17(24)18(23-12-21-11-22-23)15-5-1-14(10-20)2-6-15/h1-8,11-12,17-18,24H,9H2
|
||||
| InChIKey |
SLJZVZKQYSKYNV-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 160146-17-8
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Superpathway of steroid hormone biosynthesis | ||||
| Estradiol biosynthesis II | |||||
| Estradiol biosynthesis I | |||||
| KEGG Pathway | Steroid hormone biosynthesis | ||||
| Metabolic pathways | |||||
| Ovarian steroidogenesis | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| PathWhiz Pathway | Androgen and Estrogen Metabolism | ||||
| Reactome | Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Ovarian Infertility Genes | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010074) | ||||
| REF 2 | Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.